CVC faces shareholder revolt over €10.7bn Recordati take-private
Summary
Investors are opposing CVC's proposed €10.7bn take-private of Recordati, arguing that the offer undervalues the pharmaceutical company and that shareholders are being pressured to accept it.
The shareholder revolt turns a negotiated acquisition into a contested deal and raises the risk
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The dispute shows how perceived valuation gaps can threaten even large private equity takeovers after terms are announced.